Court rules in favor of Novartis over Glivec price

A Seoul court said on January 22 that it has ruled in favor of Novartis AG, the Swiss drug giant, who sought to overturn an earlier government decision to reduce the price of Glivec (imatinib mysylate) by 14 percent.

The Seoul Administrative Court reversed the health ministry's decision last September, saying that Glivec, the first-line drug, is not simply comparable to Sprycel, the second-l...